Izokibep, IL-17Ai, #ACR23 abs #1688 demonstrated ACR70 in 52%, PASI100 in 71% and enthesitis complete resolution in 89% at week 46. Well tolerated, no dose-related AEs, similar safety with other IL-17Ai https://t.co/TQAIVa9H2j @rheumnow https://t.co/ihzxnuAsWw

Non TNFi b/tsDMARDs vs TNFi in RA-ILD. New-User, Propensity Score Matched Study. 454 patients. No difference! resp-related hospitalisation aHR 1.22 [0.92, 1.60] No difference mortality. Abstr#1582 #ACR23 #ACRbest @RheumNow https://t.co/HzzVo9dJHi https://t.co/mZuHq4GShU

Upcoming Plenary II session Ab#1584 on Bactrim for GPA pts on RTX Should you use this for prophylaxis after weaning the prednisone? #ACR23 @RheumNow

Rather unsurprising finding at this point, but valuable nonetheless Per usual, joint efficacy for bimekizumab (IL17i) ~similar to TNF New twist; similar loss in efficacy over time. Nice to have another IL17i; not sure this is a "blockbuster" @RheumNow #ACR23 Abstr1437 https://t.co/4sVfSz7ZnK

Great Debate on the use of biologics in treatment of Giant Cell Arteritis and Polymyalgia Rheumatica! Let's begin with Dr. Robert Spiera on why we should NOT use IL-6i No evidence of disease modifying Lose biomarker activity Cost @RheumNow #ACR23 #ACRbest https://t.co/XCT02wYb2s

Here is the popular answer@to the #ACR23 debate of up front bDMARD in GCA and PMR Yes vs No. the audience has no consensus. Access is Impt, experience and criteria of who to use it in. ⁦@ACRheum⁩ ⁦@RheumNow⁩ https://t.co/7pxF4w926m

Debaters and moderators acknowledge IL6i may not be the only steroid sparing agents that would work for #GCA. Abatacept, secukinumab, JAKi are being evaluated #greatdebate @rheumnow #ACR23

The order of use will affect the safety and effectiveness of drug Rx in #Rheumatoid #arthritis So if #Rituximab is used in later line #Rx - is looks worse@than ex #TNFi used early. Never forget prescribing bias / confounding the results. @RheumNow @ACRheum #ACR23 https://t.co/JJ8BY7n9VM

More nuanced poll for #GreatDebate #ACR23 @RheumNow How should we use biologics for PMR/GCA?

#GCA Rx #bDMARD is established to #steroid spare and reduce relapses. #Tocilizumab #GiACTA Dr Seo said ‘biologics work and steroids are bad!’ ⁦@ACRheum⁩ ⁦@RheumNow⁩ #ACR23 #ACRbest https://t.co/JmSE1KKlf5